Press Releases

Recent Press Releases

7/29/2015
Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients

5/7/2015
Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen

12/11/2014
Plexxikon and QuantumLeap Healthcare Collaborative Announce Selection of PLX3397 for I-SPY 2 TRIAL in Breast Cancer

5/14/2014
Plexxikon Announces Promising Preliminary PLX3397 Phase 1 Extension Data in Patients with Pigmented Villonodular Synovitis (PVNS)

5/14/2014
Plexxikon Announces PLX3397 Data Presentations at ASCO 2014 Annual Meeting

5/31/2013
Plexxikon Announces Program Update and Management Changes

11/8/2012
Plexxikon Announces Three-Year Survival in Zelboraf-Treated Metastatic Melanoma Patients

2/19/2012
Plexxikon Announces European Approval of Zelboraf® for the Treatment of Patients with BRAF Mutation-Positive Metastatic Melanoma

12/12/2011
Plexxikon Advances Novel Targeted Treatment of PLX3397 in Blood Cancer

11/13/2011
Plexxikon Novel Agents Aim To Address Cancer Treatment in New Ways

8/17/2011
Plexxikon Announces FDA Approval of Zelboraf™ (vemurafenib) and Companion Diagnostic for the Treatment of Patients with BRAF Mutation-Positive Metastatic Melanoma

6/5/2011
Plexxikon Reports Positive Data from Phase 3 and Phase 2 Trials of Vemurafenib (PLX4032)

6/2/2011
Plexxikon Announces Combination Trials for Vemurafenib in Melanoma

5/18/2011
Plexxikon Announces Data Presentations of Oncology Pipeline, Including Phase 3 Vemurafenib Data, at ASCO 2011 Annual Meeting

5/10/2011
New Drug Applications Submitted for Vemurafenib Market Approval in Melanoma

4/4/2011
Daiichi Sankyo Completes Plexxikon Acquisition

3/8/2011
Plexxikon Initiates Phase 2 Clinical Trial in Hodgkin Lymphoma with PLX3397

2/28/2011
Daiichi Sankyo To Acquire Plexxikon

1/27/2011
Plexxikon Initiates Phase 1 Clinical Trial for Oral Rheumatoid Arthritis Agent PLX5622

1/18/2011
Plexxikon Reports Overall Survival Benefit for Melanoma Patients in PLX4032 Phase 3 Trial

1/6/2011
Plexxikon Signs Agreement with Genentech to Co-Promote PLX4032 in the US

Archived Press Releases